Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells 8,045 Shares of Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 8,045 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total value of $191,873.25. Following the sale, the chief financial officer now directly owns 108,411 shares in the company, valued at approximately $2,585,602.35. This represents a 6.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Balaji Gandhi also recently made the following trade(s):

• On Wednesday, March 26th, Balaji Gandhi sold 1,827 shares of Phreesia stock. The shares were sold at an average price of $27.46, for a total value of $50,169.42.
• On Tuesday, February 18th, Balaji Gandhi sold 5,771 shares of Phreesia stock. The stock was sold at an average price of $30.04, for a total value of $173,360.84.
• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total transaction of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total transaction of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total value of $22,555.28.

Phreesia Trading Down 4.4 %

Shares of PHR traded down $1.11 during mid-day trading on Thursday, reaching $24.09. 639,829 shares of the company’s stock traded hands, compared to its average volume of 434,457. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The stock has a market cap of $1.42 billion, a P/E ratio of -16.39 and a beta of 0.82. The stock’s 50-day moving average is $26.66 and its two-hundred day moving average is $24.25.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. grew its holdings in shares of Phreesia by 0.9% in the fourth quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock worth $1,013,000 after purchasing an additional 357 shares during the last quarter. NewEdge Advisors LLC increased its position in shares of Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock worth $107,000 after acquiring an additional 459 shares during the period. Johnson Financial Group Inc. raised its stake in shares of Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after acquiring an additional 896 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Phreesia by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares during the period. Finally, R Squared Ltd purchased a new stake in shares of Phreesia in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PHR shares. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Truist Financial upped their price target on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird lowered their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Citigroup boosted their target price on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Finally, KeyCorp increased their price target on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Phreesia has an average rating of “Buy” and an average target price of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.